These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9389357)

  • 1. Vindesine in the treatment of leukaemia.
    Gökbuget N; Hoelzer D
    Leuk Lymphoma; 1997 Aug; 26(5-6):497-506. PubMed ID: 9389357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic myelogenous leukemia in blastic crisis with chemotherapy incorporating vindesine-prednisolone.
    Uzuka Y; Saito Y
    Cancer Treat Rep; 1985 Nov; 69(11):1297-9. PubMed ID: 3867403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous infusion chemotherapy with epirubicin and vincristine in relapsed and refractory acute leukemia.
    Liso V; Specchia G; Pavone V; Capalbo S; Dione R
    Acta Haematol; 1990; 83(3):116-9. PubMed ID: 2109448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study.
    Vats T; Buchanan G; Mehta P; Ragab A; Hvizdale E; Nitschke R; Link M; Beardsley GP; Maybee D; Krischer J
    Invest New Drugs; 1992 Aug; 10(3):231-4. PubMed ID: 1428733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experience with using aclarubicin in the treatment of acute leukemia and blast crisis of chronic myeloid leukemia].
    Savchenko VG; Isaev VG; Abakumov EM; Khoroshko ND; Turkina AG; Sokolov AN; Viadro MM; Navashin SM
    Antibiot Khimioter; 1992 Jul; 37(7):47-9. PubMed ID: 1456812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia.
    Letendre L; Noel P; Tefferi A; Solberg LA; Gastineau DA; Hoagland HC
    Am J Clin Oncol; 1995 Oct; 18(5):382-4. PubMed ID: 7572751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
    Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia.
    Chen S; Wu D; Sun A; Qiu H; Jin Z; Tang X; Miao M; Fu Z; Ma X; Han Y; Hu X
    Am J Hematol; 2007 Oct; 82(10):942. PubMed ID: 17617780
    [No Abstract]   [Full Text] [Related]  

  • 11. [BH-AC.AMP protocol in the treatment of refractory childhood acute leukemia].
    Nakadate H; Hatayama Y; Hatae Y; Takeda T
    Gan To Kagaku Ryoho; 1988 Oct; 15(10):2907-10. PubMed ID: 3178240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy of chronic myelogenous leukemia--VP(M) regimen initiated during its chronic phase, and evaluation of MCNU in the phase of blastic crisis].
    Kitajima K; Adachi T; Takahashi I; Nakada H; Osada K; Fukuda S; Ohmoto E; Aoyama S; Yorimitsu S; Sanada H
    Gan To Kagaku Ryoho; 1989 Nov; 16(11):3573-9. PubMed ID: 2817908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
    Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S
    Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vindesine effect in myeloid leukemia.
    Baccarani M; Zaccaria A; Corbelli G; Tura S
    Cancer Chemother Pharmacol; 1982; 8(3):255-9. PubMed ID: 6957273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Success of the chemotherapy of cancer. The cure of leukemia].
    Lopez M
    Clin Ter; 1999; 150(6):453-62. PubMed ID: 10756667
    [No Abstract]   [Full Text] [Related]  

  • 17. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report.
    Kaspers GJ; Kardos G; Pieters R; Van Zantwijk CH; Klumper E; Hählen K; de Waal FC; van Wering ER; Veerman AJ
    Leukemia; 1994 Jul; 8(7):1224-9. PubMed ID: 8035616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia.
    Carulli G; Petrini M; Marini A; Vaglini F; Caracciolo F; Grassi B
    Haematologica; 1990; 75(6):516-21. PubMed ID: 1982999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
    Kantarjian HM; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang LY; Rios MB; Keating MJ; Meyer M
    Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimising the long-term adverse effects of childhood leukaemia therapy.
    Langebrake C; Reinhardt D; Ritter J
    Drug Saf; 2002; 25(15):1057-77. PubMed ID: 12452732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.